Galapagos buys U.K. biotech for $1.6M in cash

Cangenix, a gene-to-structure biotech firm that offers drug discovery services, has been acquired by Galapagos for $1.6 million upfront plus more than $700,000 in potential milestone fees. Galapagos said Cangenix's technology would complement its structure-based drug discovery unit, Argenta. "The assets and expertise of Cangenix really address a growing client need at Argenta. We look forward to extending and expanding this business," Galapagos CEO Onno van de Stolpe said.

View Full Article in:

Pharmaceutical Business Review Online · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC